Scientists placed 200,000 living human brain cells on a microchip and taught it how to play a doomsday video game — and are now using the dystopian tech to power AI data centers. Australian biotech ...

The new five-year plan calls for more original scientific research to facilitate the country's bid for self-reliance.

Learn more about whether Revvity, Inc. or 10x Genomics, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

A Swiss-based commercial-stage biotechnology and neurotechnology company developing digital neurotherapeutic treatments for neurological diseases and brain disorders. MindMaze Therapeutics combines ...

The biotech firm says that its platform will help reduce the production costs of notoriously pricey gene therapies.

Publishes OpenFold3 training datasets via Amazon Web Service’s (AWS) Registry of Open Data, alongside model weights, training and inference code, and evaluation scripts, enabling independent ...

Biophytis and LynxKite launch new modalities beyond MASSIVE: AI-driven drug discovery for next-generation longevity therapies -- This partnership will generate revenue through: -- A computational ...

QuTEM and Boston University collaborate to provide localized, high-speed AAV analysis for North American gene therapy ...

The government will invest about 8.6 trillion won ($5.77 billion) this year to accelerate development across various fields, ...

His job is to reimagine the future of drugmaking using that similarly trendy branch of computer science, artificial intelligence (AI). He is applying this to transferring as much of the load as ...

The AI in precision medicine market shows strong growth prospects driven by the need for personalized therapies amid rising chronic diseases. Key opportunities include advancements in AI for ...

Asset-Level Financing -- Legal and financial advisers are structuring vehicles for investors to participate directly at the program level across the proprietary portfolio.